Amarin Accused Of Pumping Up Stocks Before FDA Snub
Amarin Corp. PLC artificially inflated its stock price before a U.S. Food and Drug Administration panel denied expanded use of its fish oil drug Vascepa among adults with high fat levels,...To view the full article, register now.
Already a subscriber? Click here to view full article